Log in

Kiniksa Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KNSA)

$5.24
-0.05 (-0.95 %)
(As of 10/20/2019 05:51 AM ET)
Today's Range
$5.09
Now: $5.24
$5.49
50-Day Range
$5.21
MA: $8.17
$9.95
52-Week Range
$5.01
Now: $5.24
$28.90
Volume867,364 shs
Average Volume120,286 shs
Market Capitalization$287.41 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.35
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KNSA
CUSIPN/A
CIKN/A
Phone44-80-8189-6257

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.64 per share

Profitability

Net Income$-103,230,000.00

Miscellaneous

Employees111
Market Cap$287.41 million
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.


Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Kiniksa Pharmaceuticals.

What price target have analysts set for KNSA?

3 brokers have issued 1 year price targets for Kiniksa Pharmaceuticals' shares. Their predictions range from $26.00 to $35.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $31.33 in the next year. This suggests a possible upside of 498.0% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.

What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.

What are Wall Street analysts saying about Kiniksa Pharmaceuticals stock?

Here are some recent quotes from research analysts about Kiniksa Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. " (10/16/2019)
  • 2. Wedbush analysts commented, "Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share." (8/14/2019)

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

Media headlines about KNSA stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Kiniksa Pharmaceuticals.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,100,000 shares, an increase of 8.9% from the August 30th total of 1,010,000 shares. Based on an average daily volume of 81,500 shares, the days-to-cover ratio is currently 13.5 days. Currently, 7.3% of the company's stock are sold short. View Kiniksa Pharmaceuticals' Current Options Chain.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), Myokardia (MYOK), Athenex (ATNX), Cidara Therapeutics (CDTX), Cronos Group (CRON), CytomX Therapeutics (CTMX), Dicerna Pharmaceuticals (DRNA), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD) and Global Blood Therapeutics (GBT).

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the folowing people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 49)
  • Mr. Stephen Mahoney, Pres & COO (Age 47)
  • Dr. John F. Paolini, Chief Medical Officer (Age 53)
  • Mr. Chris Heberlig, Exec. VP & CFO (Age 43)
  • Mark Ragosa C.F.A., VP of Investor Relations

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $5.24.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $287.41 million. The company earns $-103,230,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.View Additional Information About Kiniksa Pharmaceuticals.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com/.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]


MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel